Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0N2LY
|
|||
Former ID |
DIB007131
|
|||
Drug Name |
NN-2501
|
|||
Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Discontinued in Phase 1 | [1] | |
Company |
Novo Nordisk A/S
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Glucagon receptor (GCGR) | Target Info | Antagonist | [2] |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Glucagon signaling pathway | ||||
Reactome | Glucagon signaling in metabolic regulation | |||
G alpha (q) signalling events | ||||
G alpha (s) signalling events | ||||
Glucagon-type ligand receptors | ||||
WikiPathways | GPCRs, Class B Secretin-like | |||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
Integration of energy metabolism | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018428) | |||
REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018428) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.